Laumas Sandeep's most recent trade in Unicycive Therapeutics Inc was a trade of 84,200 Restricted Stock Units done . Disclosure was reported to the exchange on May 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 84,200 | 84,200 | - | - | Restricted Stock Units | |
| Unicycive Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 84,200 | 84,200 | - | - | Restricted Stock Units | |
| Unicycive Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 47,941 | 47,941 | - | - | Restricted Stock Units | |
| Unicycive Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 42,100 | 126,300 | - | - | Restricted Stock Units | |
| Unicycive Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 42,100 | 126,300 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Sale of securities on an exchange or to another person at price $ 23.04 per share. | 10 Sep 2025 | 17,539 | 12,461 | - | 23.0 | 404,099 | Common Stock |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.60 per share. | 10 Sep 2025 | 17,000 | 17,000 | - | 11.6 | 197,200 | Common Stock |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 17,000 | 17,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2025 | 13,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. | 10 Sep 2025 | 13,000 | 30,000 | - | 12.7 | 164,840 | Common Stock |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Sale of securities on an exchange or to another person at price $ 23.88 per share. | 10 Sep 2025 | 12,461 | 0 | - | 23.9 | 297,569 | Common Stock |
| Unicycive Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 21,200 | 41,286 | - | - | Stock Options | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 44,851 | 44,851 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 45,000 | 45,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Laumas Sandeep | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2024 | 80,000 | 80,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Laumas Sandeep | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 415,000 | 415,000 | - | - | Employee Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Sandeep Laumas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Sandeep Laumas | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 234,000 | 234,000 | - | - | Employee Stock Option (right to buy) |